The natural course of post-procedural incomplete strut apposition (ISA) after the implantation of bioresorbable scaffolds (BVS) remains unknown. The purpose of the present study was to evaluate the fate of post-procedural ISA after everolimus-eluting Absorb BVS in comparison with the second-generation everolimus-eluting cobalt chromium stent (CoCr-EES). 
Introduction
Strut malapposition is a major finding in cases of early and late scaffold thrombosis of bioresorbable scaffold (Absorb BVS: Abbott Vascular, Santa Clara, CA, USA). 1 To avoid unfavourable clinical outcomes, prevention of incomplete strut apposition (ISA) would be essential. However, we often face a dilemma of residual ISA and scaffold expansion limit. Even if we find a residual ISA, we cannot expand the scaffold any more when it is close to the limit of scaffold expansion (0.5 mm þ nominal device size). 2 Nevertheless, a certain degree of ISA could be acceptable since we would expect that the ISA would spontaneously resolve during the process of neointimal growth and vascular healing. Therefore, a guidance value of ISA distance predicting resolution of ISA would be helpful for the operators to decide the procedural endpoint.
The natural course of post-procedural ISA after the implantation of bioresorbable scaffolds remains unknown to date. The purpose of the present study was to evaluate the fate of post-procedural ISA after everolimus-eluting Absorb bioresorbable vascular scaffold when compared with the second-generation everolimus-eluting cobalt chromium metallic stent (XIENCE CoCr-EES: Abbott Vascular, Santa Clara, CA, USA) using the serial optical coherence tomography (OCT) assessments.
Methods
Study design and population ABSORB Japan [NCT01844284] was a prospective, multicentre, randomized, single-blind, active-controlled clinical trial randomizing 400 patients in a 2:1 ratio to treatment with the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA: N = 266) or CoCr-EES (XIENCE Prime/ Xpedition, Abbott Vascular: N = 134). The details of the trials have been published elsewhere. 3 All patients were maintained on a thienopyridine for at least 12 months, and aspirin indefinitely. As an imaging substudy, 125 patients were allocated randomly to the OCT-1 subgroup to undergo serial OCT follow-up at post-procedure and at 2-and 3-year. The present study is a post hoc analysis in which we evaluated the 2-year follow-up OCT data from the OCT-1 subgroup. The ethics committees approved the protocol at the participating institutions. All patients provided written informed consent and were blinded to their treatment assignment through 5-year follow-up.
Procedure and 2-year imaging follow-up
The details of implantation technique were previously published. 3 In the patients sub-randomized to OCT-1 group, post-procedural OCT was performed using a frequency domain imaging system (C7/C8 system, LightLab Imaging, Westford, MA, or Lunawave system, Terumo corporation, Tokyo, Japan) at the very end of the procedure. At 2-year, coronary angiography was repeated in the same projections as at post procedure. OCT was performed in target lesion including 5 mm distal and 5 mm proximal to the stent/scaffold. The imaging data were analysed in the independent core laboratories (Quantitative Coronary Angiography [QCA]: Beth Israel Deaconess medical centre, Boston, USA, and OCT: Cardialysis, Rotterdam, the Netherlands).
OCT analysis
The OCT recordings were analysed off-line using QIVUS software (ver 3.0, MEDIS, Leiden, the Netherlands). We were unable to blind the analysts to the device type because of the specific appearance of BVS and CoCr-EES struts on OCT. Taking into account the difference in optical properties of CoCr and polylactide, OCT analysis was performed using comparative methods. 4 All OCT measurements including the ISA assessment were performed at intervals of 1.0 mm in the target segments. For BVS, ISA strut was defined by visual assessment as a strut which did not contact with vessel wall. When a strut partially contacted with the vessel wall, this strut was categorized as partial ISA. In these ISA or partial ISA, abluminal ISA distance was measured as a distance from the centre of the abluminal black core border to the adjacent lumen border, following a straight line connecting the centre of the abluminal black core border with the centre of gravity of the lumen (Figure 1 ). Endoluminal ISA distance was defined as the distance from the centre of the endoluminal black core border to the adjacent lumen border. This value was calculated as abluminal ISA distance plus 97 mm [thickness of black core of BVS = total strut thickness (157 mm) -2 Â bright border (30 mm)]. For CoCr-EES, endoluminal ISA distance was measured from the centre of the strut blooming to the adjacent lumen border, following a straight line connecting the centre of the strut blooming with the centre of gravity of the lumen (Figure 1 ). ISA strut was defined as a strut with endoluminal ISA distance > 89 mm. 4 Abluminal ISA distance was calculated as endoluminal ISA distance minus 89 mm (strut thickness of CoCr-EES).
Serial OCT images at post-stenting and 2-year follow-up were reviewed side by side on the screen, and the target site was matched based on the distance from landmarks such as branches, calcifications, or stent edges using the dedicated software QCU-CMS software version 4.69 (Leiden University Medical Center, Leiden, The Netherlands). Using this matching methodology, fate of all ISA struts and partial ISA struts at poststenting was assessed; and all the struts were categorized into either 'resolved ISA' or 'persistent ISA' (Figure 1 ).
Statistical analysis
Data are expressed as mean ± standard deviation or median and interquartile range. Group means for continuous variables with normal and non-normal distributions were compared using Student's t-tests and Mann-Whitney U tests, respectively. Categorical variables were compared using the Pearson's chi-square test or Fischer's exact test, as appropriate. Normality of distribution was tested by the Kolmogorov-Smirnov test. Mixed linear model with an assumed Gaussian distribution was used for the comparisons of continuous variables to take into an account the clustered nature of >1 scaffolds analysed from the same patients and >1 struts from the same scaffolds, which might result in unknown correlations among measurements within the clusters. Receiver-operating characteristic (ROC) curve analysis was performed at strut level to identify the best cut-off value of OCT-estimated ISA distance at post-stenting for the prediction of persistent ISA at 2-year follow-up. The best cut-off value was determined by the maximum sum of sensitivity and specificity. Statistical significance was assumed at a probability (P) value of <0.05. All statistical analyses were performed with SPSS (version 23.0.0, IBM, New York).
Results

Study population
The present study evaluated the OCT-1 subgroup of ABSORB Japan comprising 87 lesions from 83 patients in the BVS arm and 44 lesions from 43 patients in the CoCr-EES arm. Paired OCT images at baseline and 2-year follow-up were available in 112 lesions; and 2 out of the 112 lesions were excluded from the analysis since these 2 lesions had target lesion revascularization before 2-year follow-up. 
OCT findings
Results of post-procedural and 2-year follow-up OCT are tabulated in Table 3 . Post-procedure %malapposed strut and ISA area were smaller in BVS than in CoCr-EES (%malapposed strut: 4.8 ± 6.9% vs. 9.9 ± 9.8%, P = 0.002; ISA area 0.10 ± 0.18 mm 2 vs. 0.23 ± 0.26 mm 2 , P = 0.003). At 2-year follow-up, the difference diminished, and majority of the ISA struts spontaneously resolved in both arms (%malapposed strut: 0.10 ± 0.46% vs. 0.24 ± 0.65%, P = 0.183). In the BVS arm, 82% of lesions had ISA at post-procedure, while only 7% of lesions had ISA at 2-year follow-up with persistent ISA in 4% and late acquired ISA in 3%. All persistent ISA of the BVS struts were covered, whereas one third of persistent ISA of the CoCr-EES struts remained uncovered.
The results of ROC curve analysis for predicting persistent ISA are shown in Figure 2 . A total of 661 BVS struts in 73 lesions and 807 CoCr-EES struts in 37 lesions were employed for the ROC analysis. The best cut-off value of OCT-estimated endoluminal ISA distance at post-stenting for predicting persistent ISA at 2-year follow-up was 396 mm for BVS (sensitivity 0.875; specificity 0.851) and 359 mm for CoCr-EES (sensitivity 0.778; specificity 0.881).
Discussion
The main findings of the present study can be summarized as follows: (1) Post-procedure %malapposed strut and ISA area were smaller in BVS than in CoCr-EES. At 2-year follow-up, the difference diminished, and majority of the ISA struts spontaneously resolved in both Figure 1 Image examples of ISA analysis. For BVS (A-C), abluminal ISA distance was measured as a distance from the centre of the abluminal black core border to the adjacent lumen border (double-headed arrow in B), following a straight line connecting the centre of the abluminal black core border with the centre of gravity of the lumen. For CoCr-EES (D-F), endoluminal ISA distance was measured from the centre of the strut blooming to the adjacent lumen border (double-headed arrow in E), following a straight line connecting the centre of the strut blooming with the centre of gravity of the lumen. All the ISA struts post-stenting were categorized into either 'resolved ISA (white arrow)' or 'persistent ISA (white arrowhead)'. *Metallic marker. Abbreviations: ISA, incomplete strut apposition; BVS, bioresorbable vascular scaffold; CoCr-EES, cobalt-chromium everolimus-eluting stents. arms; (2) The best cut-off value of OCT-estimated endoluminal ISA distance at post-stenting for predicting persistent ISA at 2-year follow-up was 396 mm for BVS (sensitivity 0.875; specificity 0.851) and 359 mm for CoCr-EES (sensitivity 0.778; specificity 0.881). Larger ISA distance could be tolerable for BVS implantation compared to CoCr-EES implantation; (3) OCT could provide useful information for the optimization of PCI with BVS and CoCr-EES.
Post-procedure ISA
Post procedure ISA can occur after stent/scaffold implantation in our daily clinical practice. Nevertheless, a certain degree of ISA could be acceptable as a procedure endpoint.
In the era of drug eluting stents (DES), a previous OCT study has demonstrated that the distance between the stent strut and vessel wall > 280 mm and > 260 mm immediately after an index procedure was the corresponding cut-off point for predicting persistent ISA at 8-month follow-up in the first-generation sirolimus-eluting stents and paclitaxel-eluting stents, respectively. 5 The second-generation CoCr-EES showed better healing of post-procedural ISA in comparison with the first-generation sirolimus-eluting stents. The cut-off value for the prediction of persistent ISA was > 355 mm, 6 which is quite similar to our results (359 mm). However, there was no definite guidance value for ISA distance of BVS to date. The present study demonstrated the best cutoff value of endoluminal ISA distance (396 mm) for BVS implantation (sensitivity 0.875; specificity 0.851) for the prediction of persistent ISA at 2-year follow-up. We often face the dilemma of ISA and scaffold expansion limit. Our results would serve in our daily clinical practice as a guidance value for the optimization of BVS implantation.
Improvement of ISA in bioresorbable scaffold and metallic stent
The present study demonstrated that larger ISA distance could be acceptable for BVS implantation compared to CoCr-EES implantation. Although various factors may be associated with the healing process of ISA in BVS and CoCr-EES, several studies would support the fact that ISA distance post-procedure is the most relevant factors for the improvement of ISA. [5] [6] [7] The randomized fashion of the present study could eliminate any confounding factors when we compared the two devices, i.e. in terms of patient demographics, procedural characteristics, medications during follow-up, etc. Moreover, both devices have the same anti-proliferative drug (everolimus) and One of the possible explanations for the wider safety margin of the acceptable ISA distance of BVS than that of CoCr-EES is the unique property of BVS: i.e. the ability to enlarge and follow the vessel adaptive remodelling after the loss of mechanical integrity which usually occur 6 months after the implantation. Post-procedure ISA could be resolved during the process of transient constrictive remodelling after PCI followed by adaptive remodelling of the vessel. 8, 9 Metallic cage cannot adapt this dynamic vessel wall change, whereas polymeric scaffold can do due to the feature of temporal vessel support. The second possibility is the difference in disturbance of laminar blood flow. Larger strut thickness and strut footprint of BVS (157 mm, 27%) compared to CoCr-EES (89 mm, 13%) could create greater zone of recirculation and low endothelial shear stress area, which would enhance the neointimal growth and tissue filling behind the ISA struts. Fate of acute ISA of BVS and CoCr-EES
ISA and scaffold/stent thrombosis
The role of ISA in the pathogenesis of stent/scaffold thrombosis still remains controversial, and the evidence is limited. 12 With regard to stent thrombosis following DES implantation, although several studies have been conducted to clarify the relationship between ISA and adverse cardiovascular events, only a few studies have demonstrated such relationship. 12 Guagliumi et al. demonstrated by combined IVUS and OCT assessments that the presence and magnitude (i.e. area and distance) of ISA were significantly higher in patients with DES thrombosis compared with those without DES thrombosis. 13 Parodi et al.
reported precise OCT assessments in 23 patients with subacute and late/very late stent thromboses. Subacute and late/very late stent thromboses were both characterized by higher malapposed and uncovered struts, and these findings were mainly located at the thrombus site of the culprit stent. 14 A prospective IVUS study demonstrated that the presence of ISA as assessed by IVUS 8 months after DES implantation was associated with a higher rate of myocardial infarction and very late stent thrombosis during 5 years long-term follow-up. 15 Cook et al. correlated the histopathology of thrombus aspirates with IVUS findings in patients with very late DES thrombosis. 16 They established a correlation between the amount of eosinophil infiltrates with the extent of positive vessel remodelling, suggesting hypersensitivity reactions of all three layers of the vessel wall in patients with ISA. Although the previous studies showed a higher incidence of ISA in patients with DES thrombosis, it should be underlined that ISA is not an isolated factor responsible for DES thrombosis. Inflammatory reaction and subsequent vessel remodelling coexisting with ISA would be a major cause of DES thrombosis.
12
Regarding scaffold thrombosis following BVS implantation, no comprehensive study on BVS-ISA has been conducted so far. Our group recently reported that strut malapposition was the most frequent OCT finding in the published 43 case reports on early and late scaffold thrombosis. In contrast to DES thrombosis, the programed biodegradation process of BVS could play a role in scaffold thrombosis in case struts are not covered by neointima and late discontinuity lets protruded part of the struts into the lumen and brings thrombogenic proteoglycan (poly-L-lactic acid products) into contact with blood. Therefore, enhancement of neointimal coverage would be a key to prevent scaffold thrombosis. Prevention of malapposition by either BVS-specific implantation strategy 19 or OCT-guided implantation, 20 and new generation BVS with thinner struts with stronger radial force, smaller footprint, circular geometric shape instead of quadratic configuration, self-correction properties, and higher resistance to fracture allowing overexpansion could contribute to early neointimal coverage and consequent reduction of the incidence of scaffold thrombosis. Although the impact of ISA on stent/scaffold thrombosis is still a matter of debate, the prospective evaluation would be ethically challenging. Based on the retrospective data, it would be recommended to correct post-procedure ISA as much as possible within the limit of scaffold expansion, and the cutoff value we presented in the current analysis could guide the decision making for the treatment of residual ISA.
Study strength and limitations
We evaluated natural course of ISA in the context of randomized controlled trial comparing BVS and CoCr-EES in which the largest series of serial OCT images are available for the time being. The cutoff value of CoCr-EES was quite similar to the previous reported one, 6 which supports the credibility of our analysis. Some limitations need to be acknowledged for the current study. First, we assessed the fate of ISA only at 2 years follow-up. Majority of the previous studies in DES era evaluated the natural course of ISA at 8-12 months after the index procedure. [5] [6] [7] Our follow-up period is relatively longer than the previous ones. However, it might be acceptable considering the fact that the neointimal growth stops at a certain point (2-6 weeks in the animal model). 21 The almost identical results of CoCr-EES (359 mm) in our analysis with the previous report (355 mm) would also support its validity. Second, late acquired ISA was beyond the scope of our study. Third, although we employed the comparative OCT methodology for BVS and CoCr-EES, the inherent dissimilarity of material and shape between both devices could still result in a possible difference in the assessment of ISA. Lastly, the present results would be limited by the nature of a post-hoc study, and should be interpreted with caution. Further prospective study would be warranted.
Conclusions
BVS as compared with CoCr-EES allows larger ISA distance at postprocedure, although we should make every effort to minimize the post-procedure ISA. The reported cut-off value of OCT-estimated ISA distance at post-stenting for predicting persistent ISA would be helpful information to optimize PCI with BVS and CoCr-EES.
